Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):507-11. doi: 10.1016/j.clml.2011.06.010. Epub 2011 Aug 2.
PCL carries a poor prognosis and the optimal management remains unknown.
To evaluate the outcome of patients with PCL in the era of novel agents and innovative transplantation strategies, we conducted a review of patients with PCL who were treated at our institution from August 2003 to October 2009. Our primary endpoint was to determine overall survival, which was calculated from time of PCL diagnosis to death or last follow-up. Secondary endpoints included response rates and analyses regarding how the novel agents and presence of adverse cytogenetic analyses affected outcomes.
We identified 25 patients with PCL (13 with primary PCL [pPCL], 12 with secondary PCL [sPCL]) from our institution. Eighteen patients received bortezomib-based regimens, 19 received high-dose melphalan followed by autologous hematopoietic stem cell transplantation (HCT), and 6 underwent allogeneic HCT. The median overall survival for all patients was 23.6 months. Bortezomib-treated patients had a median survival of 28.4 months vs. 4.0 months for the non-bortezomib-treated group (P < .001).
Our analysis suggests that patients with PCL who were treated with bortezomib and/or allogeneic HCT had improved outcomes.
PCL 预后较差，其最佳治疗方法仍不清楚。
为了评估新型药物和创新移植策略时代 PCL 患者的治疗效果，我们回顾性分析了 2003 年 8 月至 2009 年 10 月在我院接受治疗的 PCL 患者。我们的主要终点是确定总体生存率，即从 PCL 诊断到死亡或末次随访的时间。次要终点包括反应率，以及新型药物和不良细胞遗传学分析的存在对结果的影响。
我们从我院确定了 25 例 PCL 患者（原发性 PCL 13 例，继发性 PCL 12 例）。18 例患者接受硼替佐米为基础的方案治疗，19 例患者接受大剂量美法仑联合自体造血干细胞移植（HCT），6 例患者接受异基因 HCT。所有患者的中位总生存期为 23.6 个月。接受硼替佐米治疗的患者中位生存时间为 28.4 个月，而未接受硼替佐米治疗的患者中位生存时间为 4.0 个月（P<0.001）。
我们的分析表明，接受硼替佐米和/或异基因 HCT 治疗的 PCL 患者的预后得到改善。
